Brookstone Capital Management increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 18.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,389 shares of the medical equipment provider's stock after acquiring an additional 3,287 shares during the period. Brookstone Capital Management's holdings in Intuitive Surgical were worth $10,593,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Atala Financial Inc bought a new position in shares of Intuitive Surgical during the fourth quarter valued at about $25,000. Parvin Asset Management LLC bought a new position in Intuitive Surgical during the 4th quarter valued at approximately $26,000. Global Financial Private Client LLC raised its position in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 38 shares during the last quarter. Hurley Capital LLC bought a new position in Intuitive Surgical during the 4th quarter valued at approximately $28,000. Finally, Summit Securities Group LLC bought a new position in Intuitive Surgical during the 4th quarter valued at approximately $30,000. Institutional investors own 83.64% of the company's stock.
Insiders Place Their Bets
In related news, EVP Gary Loeb sold 1,700 shares of Intuitive Surgical stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the sale, the executive vice president directly owned 2,245 shares in the company, valued at approximately $1,152,089.10. This trade represents a 43.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $515.91, for a total value of $96,991.08. Following the completion of the sale, the executive vice president owned 5,224 shares of the company's stock, valued at $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock worth $2,611,577 in the last 90 days. 0.70% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Erste Group Bank upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Thursday, June 5th. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, April 14th. Evercore ISI decreased their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday, April 23rd. Finally, Piper Sandler decreased their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus target price of $588.95.
Check Out Our Latest Report on ISRG
Intuitive Surgical Stock Down 1.8%
Shares of NASDAQ:ISRG traded down $9.76 on Monday, hitting $534.71. 1,191,600 shares of the company traded hands, compared to its average volume of 1,670,783. The company has a market cap of $191.65 billion, a PE ratio of 78.40, a PEG ratio of 5.78 and a beta of 1.64. Intuitive Surgical, Inc. has a 52 week low of $413.82 and a 52 week high of $616.00. The stock has a 50 day simple moving average of $537.53 and a 200-day simple moving average of $536.99.
Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. During the same period last year, the business earned $1.50 EPS. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.
About Intuitive Surgical
(
Free Report)
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Featured Articles

Before you consider Intuitive Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intuitive Surgical wasn't on the list.
While Intuitive Surgical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.